Meatal Swab Yourself With Testing for Infections Collectively

NCT ID: NCT05870098

Last Updated: 2023-12-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

1250 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-07-18

Study Completion Date

2024-08-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this study is

1. to improve the accuracy of chlamydia multi-site testing in men who have sex with men (MSM) and trans-women, whilst saving diagnostic costs, by comparing two new pooling methods with the 3-samples tested separately
2. to assess the diagnostic accuracy of pooled specimens for lymphogranuloma venereum detection (LGV) - a type of chlamydia infection

Chlamydia and gonorrhoea testing for MSM and trans-women usually involves 3 samples from the throat, bum and wee-pipe. The tests can be combined into a single sample pot (pooled sample) which reduces costs, but in a previous study this reduced the accuracy for finding chlamydia.

The main question for this study is:

Can the accuracy of chlamydia testing in a pooled sample be improved by reducing the amount of urine added to minimise dilution, or by using a meatal sample instead of a urine sample?

Participants will be asked to complete two sets of their own throat and bum samples, and then combine these into two pooled samples with 1)a meatal swab and 2)a smaller amount of first catch urine. The order of these samples will be randomised. These samples will be compared against separate samples taken at the same visit, to see how accurate the pooled samples are at diagnosing chlamydia and gonorrhoea with the different sampling techniques.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Testing for chlamydia and gonorrhoea in men who have sex with men (MSM) and trans-women is recommended every three months for those taking HIV Pre-Exposure Prophylaxis (PrEP). Testing requires throat and bottom samples, and samples from the urethra (wee-pipe), usually a urine sample. However, many sexual health services struggle to afford the costs of these 3-samples, four-times per year, which may restrict numbers given PrEP.

The investigators' previous research has shown that the 3-samples (throat, bottom, urine) can be combined into one pooled specimen to accurately find gonorrhoea and reduce laboratory costs. However, the chlamydia results of pooled samples were not as good, finding only 92 out of 100 infections compared with 99 out of 100 with 3 separate samples. The investigators' past research showed no difference in diagnostic accuracy between clinician and self-taken rectum and pharynx swabs for NG and CT detection. People prefer to take their own swabs and self-taken swabs were more cost effective than clinician taken. Self-taken swabs are now used routinely in clinical practice and are available as on-line ordered commercial kits.

This study aims to improve the accuracy of chlamydia results by comparing two new pooling methods with the 3-samples tested separately.

MSM, and trans-women, aged 18 years or over, attending a large UK city sexual health service for chlamydia and gonorrhoea testing will be invited to take part in the study.

The pooling methods will be: 1) pooling with a smaller amount of urine to reduce the dilution of the other samplesÍž and 2) pooling with a swab sample from the outside of the tip of the penis (meatal swab) instead of urine. Meatal swabs are taken by the person themselves. The swab does not go inside the penis so is easy to do and not painful. Studies suggest meatal swabs may be better at finding chlamydia than urine samples.

To ensure an accurate comparison, the order of taking the two pooling method samples, and the 3-samples tested separately, will be randomised.

The study will recruit 1250 participants. This is a large enough number to show if either of the pooling methods can detect more chlamydia than 92 out of 100 infections.

If a pooling technique was developed for MSM and trans-women that did not reduce diagnostic sensitivity, this would likely be implemented. A sensitive, low-cost, method of triple-site STI testing, available on-line, or using minimal in-house staff, would enable increased testing. The investigators believe this study will identify such a method by using meatal swabs or a reduced urine volume. The reduced diagnostic costs of almost two-thirds would enable sexual health clinics to provide PrEP to more people, and/or utilise the money saved elsewhere in their service.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chlamydia Gonorrhea

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Diagnostic accuracy study Single group receiving standard care plus two new comparators
Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Laboratory staff will be masked and will not be able to link pooled samples (sent under a unique study number) to comparator standard care separate samples (sent under a unique patient identifier).

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

All participants

All participants will receive:

1. Clinician or self-taken, pharyngeal and rectal swabs with FCU analysed individually
2. Self-taken pharyngeal, meatal, and rectal swabs analysed as a pooled specimen
3. Self-taken pharyngeal and rectal swabs with 1.5ml FCU analysed as a pooled specimen The FCU will be done after any meatal swabs. Patients will be instructed to only pass the first 5ml into the tube, and the tube will be pre-marked with a black line. Full pictoral instructions and verbal support will be given to enable them to complete the pooling process of the swabs and urine.

Group Type OTHER

All participants

Intervention Type DIAGNOSTIC_TEST

1. Clinician or self-taken, pharyngeal and rectal swabs with FCU analysed individually
2. Self-taken pharyngeal, meatal, and rectal swabs analysed as a pooled specimen
3. Self-taken pharyngeal and rectal swabs with 1.5ml FCU analysed as a pooled specimen The FCU will be done after any meatal swabs. Patients will be instructed to only pass the first 5ml into the tube, and the tube will be pre-marked with a black line. Full pictoral instructions and verbal support will be given to enable them to complete the pooling process of the swabs and urine.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

All participants

1. Clinician or self-taken, pharyngeal and rectal swabs with FCU analysed individually
2. Self-taken pharyngeal, meatal, and rectal swabs analysed as a pooled specimen
3. Self-taken pharyngeal and rectal swabs with 1.5ml FCU analysed as a pooled specimen The FCU will be done after any meatal swabs. Patients will be instructed to only pass the first 5ml into the tube, and the tube will be pre-marked with a black line. Full pictoral instructions and verbal support will be given to enable them to complete the pooling process of the swabs and urine.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 years and over. Willing to perform self-taken swabs in addition to any clinician required swabs. Able to provide informed consent

Exclusion Criteria

\- Antibiotics taken in the past 14 days (excluding metronidazole). Previous participation in this trial
Minimum Eligible Age

18 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

The Leeds Teaching Hospitals NHS Trust

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Janet Wilson, MB ChB

Role: PRINCIPAL_INVESTIGATOR

Leeds Teaching Hospitals NHS Trust

Harriet Wallace, MB ChB

Role: PRINCIPAL_INVESTIGATOR

Leeds Teaching Hospitals NHS Trust

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Leeds Teaching Hospitals NHS Trust

Leeds, West Yorkshire, United Kingdom

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Janet Wilson, MB ChB

Role: CONTACT

Phone: 00 44 113 3920323

Email: [email protected]

Harriet Wallace, MB ChB

Role: CONTACT

Phone: 00 44 113 3920323

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Janet Wilson, MB ChB

Role: primary

Harriet Wallace, MB ChB

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

GU19-125925

Identifier Type: -

Identifier Source: org_study_id